Genentech investing $450M to expand Oceanside facility (California, USA)

Roche’s Genentech is investing US$450M in expanding its biologics capabilities at Oceanside California. Approximately US$280M will go toward building a new biologics manufacturing facility that will begin operations in 2025. The new facility will produce protein-based medicines and antibodies, and will have capacity to manufacture small batches of drugs including personalised medicines and treatments for patients with rare diseases.